Valeant Pharmaceuticals International, Inc. 4
4 · Valeant Pharmaceuticals International, Inc. · Filed Oct 28, 2013
Insider Transaction Report
Form 4
Weldon Ryan
EVP, Company Group Chairman
Transactions
- Exercise/Conversion
Common Stock, no par value
2013-10-24+15,521→ 90,590 total - Tax Payment
Common Stock, no par value
2013-10-24−8,051→ 82,539 total - Exercise/Conversion
Restricted Share Units
2013-10-24−15,521→ 0 total→ Common Stock (15,521 underlying)
Footnotes (3)
- [F1]This represents the number of units vested on the performance-based RSUs ("PSUs") that were previously reported on the original Form 4. The initial grant was reported to vest based on total shareholder return (TSR) between a price of $26.51 starting on September 28, 2010 and the average stock price for the 20 trading days starting on each measurement dates: 25% on June 28, 2013, 50% on September 28, 2013 and 25% on December 28, 2013. Unit vesting is contingent on TSR performance between 15% and 45% into between one and three shares of common stock, respectively, with early vesting possible at higher TSR levels. The maximum amount of PSUs has been achieved and paid out.
- [F2]This number represents common shares purchased by the officer, common shares received upon settlement and/or exercise of previously granted equity awards, as well as other outstanding equity awards that were previously reported in Table 1.
- [F3]This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Performance Share Units.